Growing evidence indicates that disruption of circadian rhythms may be a risk factor for the development of glioma. However, the molecular mechanisms underlying the genetic regulation of circadian rhythms in glioma cells have yet to be explored.
Methods and study design
Using immunohistochemical staining and methylation-specific PCR techniques, we examined the expression of the period 2 (PER2) gene, one of the most important clock genes, epidermal growth factor receptor (EGFR), and proliferating cell nuclear antigen (PCNA) in 92 gliomas.
Results
Our results revealed disturbances in the expression of PER2 in most (52.17%) glioma cells compared with the expression in nearby noncancerous cells, and indicated that PER2 gene deregulation most likely occurs via methylation of PER2 promoters. The protein expression of PCNA and EGFR was significantly higher in highgrade than low-grade gliomas (P <0.05). Furthermore, a negative correlation was detected between the protein expression of PER2 and PCNA and EGFR in glioma.
Conclusions
Because the circadian clock regulates the expression of cell cycle-related genes, we suggest that disturbances in PER2 gene expression may disrupt the regulation of the circadian clock, thus enhancing the survival of cancer cells and promoting carcinogenesis.
ReppertS.M., WeaverD.R.: Coordination of circadian timing in mammals.Nature, 418: 935–941, 2002.
2.
MorseD., SassoneC.P.: Time after time: inputs to and outputs from the mammalian circadian oscillators.Trends Neurosci, 25: 632–637, 2002.
3.
CzeislerC.A., DuffyJ.F., ShanahanT.L., BrownE.N., MitchellJ.F., RimmerD.W., RondaJ.M., SilvaE.J., AllanJ.S., EmensJ.S., DijkD.J., KronauerR.E.: Stability, precision, and near-24-hour period of the human circadian pacemaker.Science, 284: 217–281, 1999.
PandaS., AntochM.P., MillerB.H., SuA.I., SchookA.B., StraumeM., SchultzP.G., KayS.A., TakahashiJ.S., HogeneschJ.B.: Coordinated transcription of key pathways in the mouse by the circadian clock.Cell, 109: 307–320, 2002.
6.
StorchK.F., LipanO., LeykinI., ViswanathanN., DavisF.C., WongW.H., WeitzC.J.: Extensive and divergent circadian gene expression in liver and heart.Nature, 417: 78–83, 2002.
ZhengB., AlbrechtU., KaasikK., SageM., LuW., VaishnavS., LiQ., SunZ.S., EicheleG., BradleyA., LeeC.C.: Nonredundant roles of the mPer1 and mPer2 genes in the mammalian circadian clock.Cell, 105: 683–694, 2001.
11.
FuL., LeeC.C.: The circadian clock: pacemaker and tumour suppressor.Nat Rev Cancer, 3: 350–361, 2003.
12.
CanapleL., KakizawaT., LaudetV.: The days and nights of cancer cells.Cancer Res, 63: 7545–7552, 2003.
13.
ChenS.T., ChooK.B., HouM.F., YehK.T., KuoS.J., ChangJ.G.: Deregulated expression of the PER1, PER2 and PER3 genes in breast cancers.Carcinogenesis, 26: 1241–1246, 2005.
14.
MingY.Y., WenC.Y., PaiM.L., HsuJ.F., HsiaoH.H., LiuY.C., TsaiH.J., ChangC.S., LinS.F.: Altered expression of circadian clock genes in human chronic myeloid leukemia.J Biol Rhythms, 26: 136–148, 2011.
15.
GeryS., VirkR.K., ChumakovK., YuA., KoefflerH.P.: The clock gene Per2 links the circadian system to the estrogen receptor.Oncogene, 26: 7916–7920, 2007.
YangM.Y., LiuY.C., LinS.F., TangK.P., ChenY.H., LinH.Y., LiuT.C., HsiaoH.H., LiuY.C., LinS.F.: Downregulation of circadian clock genes in chronic myeloid leukemia: alternative methylation pattern of hPER3.Cancer Sci, 97: 1298–1307, 2006.
18.
XiaH.C., NiuZ.F., MaH., CaoS., HaoS.C., LiuZ.T., WangF.: Deregulated expression of the Per1 and Per2 in human gliomas.Can J Neurol Sci, 37: 365–370, 2010.
SunC.M., HuangS.F., ZengJ.M., LiuD.B., XiaoQ., TianW.J., ZhuX.D., HuangZ.G., FengW.L.: Per2 inhibits K562 leukemia cell growth in vitro and in vivo through cell cycle arrest and apoptosis induction.Pathol Oncol Res, 16: 403–411, 2010.
21.
FuyukiS., ChihiroN., YangL., YangL., SuzukiT., KondoJ., MorohashiS., ImaizumiT., KatoY., KijimaH.: PERIOD1 is an anti-apoptotic factor in human pancreatic and hepatic cancer cells.J Biochem, 146: 833–838, 2009.
22.
DuffieldG.E., BestJ.D., MeurersB.H., BittnerA., LorosJ.J., DunlapJ.C.: Circadian programs of transcriptional activation, signaling, and protein turnover revealed by microarray analysis of mammalian cells.Curr Biol, 12: 551–557, 2002.
23.
KornmannB., PreitnerN., RifatD., FleuuryO.F., SchiblerU.: Analysis of circadian liver gene expression by ADDER, a highly sensitive method for the display of differentially expressed mRNAs.Nucl Acids Res, 29: E51, 2001.
HrusheskyW.J.M., BjarnasonG.A.: Circadian cancer therapy.J Clin Oncol, 11: 1403–1417, 1993.
26.
LeviF.: Circadian chronotherapy for human cancers.Lancet Oncol, 2: 307–315, 2001.
27.
YehK.T., YangM.Y., LiuT.C., ChenJ.C., ChanW.L., LinS.F., ChangJ.G.: Abnormal expression of Period 1 (Per1) in endometrial carcinoma.J Pathol, 206: 111–120, 2005.
28.
MatsuoT., YamaguchiS., MitsuiS., EmiA., ShimodaF., OkamuraH.: Control mechanism of the circadian clock for timing of cell division in vivo.Science, 302: 255–259, 2003.
29.
FuL., PelicanoH., LiuJ., HuangP., LeeC.: The circadian gene Period2 plays an important role in tumor suppression and DNA damage response in vivo.Cell, 111: 41–50, 2002.
30.
MazzoccoliG., PiepoliA., CarellM., PanzaA., PazienzaV., BenegiamoG., PalumboO., RanieriE.: Altered expression of the clock gene machinery in kidney cancer patients.Biomed Pharmacother, 66: 175–179, 2012.
